Zurück
beenden Zusammenarbeit mit Bayer,Geld für den Prozess gegen Aventis Pharmaceuticals wird sehr knapp....naja wenn du das positiv findest
Anzeige
Meldung des Tages: Kupfer vor dem Engpass: Warum Kupfer gerade zur „Nvidia“ unter den Rohstoffen wird
jetzt mal schnelle 100% mit PHAR
Beiträge:
38
Zugriffe: 4.161 / Heute: 2
Zugriffe: 4.161 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +93,26%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +55,38%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +55,30%
Xtrackers CSI500 Swap UCITS ETF 1C
Perf. 12M: +55,12%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +54,13%
Nachricht ist wieso reden viele vom turnaround potenzial? Das muss das wohl gelogen sein oder? Dann kann sie nur noch fallen oder?
Gruß Willy
Gruß Willy
alles gelogen ist und die nur fallen können, lol
ich lach mich schlapp.
mein gott kauft oder lasst es, ist halt ein zock, für Risiken und nebenwirkungen fragen sie ihren Arzt oder Kicky.
gruß Grenke
ich lach mich schlapp.
mein gott kauft oder lasst es, ist halt ein zock, für Risiken und nebenwirkungen fragen sie ihren Arzt oder Kicky.
gruß Grenke
das sind doch keine OTCler oder ?
scheint aber nich viel zu tun im Moment ...
scheint aber nich viel zu tun im Moment ...
positives abzuzeichnen.
Die Experten des Anlegermagazins "Der Aktionär" sehen bei der Pharmanetics-Aktie (ISIN US71713J1079/ WKN 917797) Turnaroundpotenzial.
Die Meinungsverschiedenheiten hätten zu Kursverlusten bei Phamanetics geführt, wobei allerdings Gerüchten zufolge sich der Streit dem Ende nähere.
Die Experten von "Der Aktionär" sind der Meinung, dass die Pharmanetics-Aktie Turnaroundpotenzial besitzt, wobei das Kursziel 5,00 Euro beträgt und ein Stopp bei 1,20 Euro gesetzt werden soll.
Die Experten des Anlegermagazins "Der Aktionär" sehen bei der Pharmanetics-Aktie (ISIN US71713J1079/ WKN 917797) Turnaroundpotenzial.
Die Meinungsverschiedenheiten hätten zu Kursverlusten bei Phamanetics geführt, wobei allerdings Gerüchten zufolge sich der Streit dem Ende nähere.
Die Experten von "Der Aktionär" sind der Meinung, dass die Pharmanetics-Aktie Turnaroundpotenzial besitzt, wobei das Kursziel 5,00 Euro beträgt und ein Stopp bei 1,20 Euro gesetzt werden soll.
Ich konnte nirgends neuigkeiten finden. Warum ging es bergab? Was ist denn da los?
innerhalb eines monats von 2€ auf 70cents - siehst nach insiderverkauf aus...hmm
den Vertrag mit Bayer auslaufen lassen,alle Leute entlassen bis auf den CEO,der noch immer versucht,Lizenz(intellectual Property) und Gebäude zu verkaufen
PharmaNetics, Inc. (the “Company” or “PharmaNetics”), is a holding company incorporated in North Carolina in 1998 as the parent company of Cardiovascular Diagnostics, Inc. Cardiovascular Diagnostics, Inc. (“CVDI”) was incorporated in 1985 and was the sole operating subsidiary of PharmaNetics until PharmaNetics ceased substantially all of its operations in March 2004.
Prior to ceasing substantially all of its operations in March 2004 (see “Recent Developments” below), PharmaNetics developed, manufactured and marketed rapid diagnostics to dose, manage and screen patients on drugs affecting coagulation. The Company’s products are a proprietary analyzer and dry chemistry tests and controls, known as the Thrombolytic Assessment System, or TAS, that provide a physician, at the point of patient care, information that can affect therapy. The Company’s tests were and can be used in the treatment of a variety of adverse conditions caused by abnormal blood clotting in different areas of the body, including angina, heart attack, stroke, deep vein thrombosis and pulmonary and arterial emboli.
In November 2003, the Company filed a lawsuit in the eastern district of North Carolina against Aventis Pharmaceuticals, Inc. (“Aventis”). The Company, in cooperation with Aventis, has developed a rapid bedside test, known as the Enox test, that the Company believes enhances the way Lovenox®, a popular anti-blood clotting drug marketed by Aventis, currently is managed. The Company believes the test has the potential to facilitate the drug’s use in patients in the cardiac community who stand to benefit from its use. Aventis collaborated with the Company in a multi-million dollar project in which it made milestone payments to the Company to develop and co-promote the test together with Lovenox for targeted patient populations. The lawsuit alleges that Aventis has engaged in false and misleading advertising of Lovenox, which damaged the Company’s efforts to market and sell the Enox test card.
und in diesem Prozess wurde zwar bestätigt dass die Angaben von Aventis irreführensd seien,aber Aventis wurde nicht verurteilt
As of the date of this filing, pursuant to notice duly given, the Company has allowed the distribution agreement with Bayer to expire and has terminated the Enox contract sales and technical service force. Because no buyer of the manufacturing operations or intellectual property has yet emerged, effective by the end of March 2004, the Company has ceased developing, producing and selling all of its products and plans to terminate substantially all remaining employees except the chief executive officer (CEO). The Company plans to retain the CEO to manage the Aventis litigation until it is completed or settled and to continue to seek a buyer of the operations, manufacturing assets and intellectual property
www.pinksheets.com/quote/filings.jsp?symbol=PHAR
hier 8K v.5.5. und 10K v.14.4.
da hat sich wohl jemand von dem damals engagierten Finanzberater Davenport & CO einlullen lassen,als er diese Aktie empfahl ggg
PharmaNetics, Inc. (the “Company” or “PharmaNetics”), is a holding company incorporated in North Carolina in 1998 as the parent company of Cardiovascular Diagnostics, Inc. Cardiovascular Diagnostics, Inc. (“CVDI”) was incorporated in 1985 and was the sole operating subsidiary of PharmaNetics until PharmaNetics ceased substantially all of its operations in March 2004.
Prior to ceasing substantially all of its operations in March 2004 (see “Recent Developments” below), PharmaNetics developed, manufactured and marketed rapid diagnostics to dose, manage and screen patients on drugs affecting coagulation. The Company’s products are a proprietary analyzer and dry chemistry tests and controls, known as the Thrombolytic Assessment System, or TAS, that provide a physician, at the point of patient care, information that can affect therapy. The Company’s tests were and can be used in the treatment of a variety of adverse conditions caused by abnormal blood clotting in different areas of the body, including angina, heart attack, stroke, deep vein thrombosis and pulmonary and arterial emboli.
In November 2003, the Company filed a lawsuit in the eastern district of North Carolina against Aventis Pharmaceuticals, Inc. (“Aventis”). The Company, in cooperation with Aventis, has developed a rapid bedside test, known as the Enox test, that the Company believes enhances the way Lovenox®, a popular anti-blood clotting drug marketed by Aventis, currently is managed. The Company believes the test has the potential to facilitate the drug’s use in patients in the cardiac community who stand to benefit from its use. Aventis collaborated with the Company in a multi-million dollar project in which it made milestone payments to the Company to develop and co-promote the test together with Lovenox for targeted patient populations. The lawsuit alleges that Aventis has engaged in false and misleading advertising of Lovenox, which damaged the Company’s efforts to market and sell the Enox test card.
und in diesem Prozess wurde zwar bestätigt dass die Angaben von Aventis irreführensd seien,aber Aventis wurde nicht verurteilt
As of the date of this filing, pursuant to notice duly given, the Company has allowed the distribution agreement with Bayer to expire and has terminated the Enox contract sales and technical service force. Because no buyer of the manufacturing operations or intellectual property has yet emerged, effective by the end of March 2004, the Company has ceased developing, producing and selling all of its products and plans to terminate substantially all remaining employees except the chief executive officer (CEO). The Company plans to retain the CEO to manage the Aventis litigation until it is completed or settled and to continue to seek a buyer of the operations, manufacturing assets and intellectual property
www.pinksheets.com/quote/filings.jsp?symbol=PHAR
hier 8K v.5.5. und 10K v.14.4.
da hat sich wohl jemand von dem damals engagierten Finanzberater Davenport & CO einlullen lassen,als er diese Aktie empfahl ggg
hallo zusammen!
wer kennt sich denn mit diesem wert aus?
gebt mir mal bitte informationen, die mich
weiterbringen ....
lg, bull
wer kennt sich denn mit diesem wert aus?
gebt mir mal bitte informationen, die mich
weiterbringen ....
lg, bull
PharmaNetics, Inc. (PHAR.OB) announced today that it has filed a Form 15 to deregister its common stock and suspend its reporting obligations under the Securities Exchange Act of 1934, effective immediately upon such filing on May 13, 2005. As a result of the filing of the Form 15, the Company's obligation to file with the SEC virtually all reports and forms, including its quarterly and annual reports, has terminated. In addition, the common stock of the Company will no longer be quoted on the OTC Bulletin Board.
(hättest ja wirklich mal auf den Link und News klicken können !wer zockt auch mit sonem Wert!)
(hättest ja wirklich mal auf den Link und News klicken können !wer zockt auch mit sonem Wert!)
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem PHARMSTAR PHARM INC Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 37 | jetzt mal schnelle 100% mit PHAR | grenke | Kicky | 27.05.05 07:50 |